undamentalytics Newsletter
Sign in

Verrica Pharmaceuticals Inc. revenue

Verrica Pharmaceuticals Inc.'s revenue was $35.6m in fiscal 2025, up 370.2% on the year before. Since fiscal 2021 ($12.0m) it has grown at a compound 31.2% a year. Over the last twelve months it was $30.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue129583630
Growth on the year before—−24.7%−43.3%+47.7%+370.2%—
Gross profit——55——
Gross margin——90.2%65.6%——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
License and Collaboration Revenue $20.3M ▲ 1945.6%
Products $15.3M ▲ 132.5%
License and Collaboration Revenue Commercial Supply and Development $2.3M ▲ 130.0%

These categories overlap or exclude eliminations, so shares aren't shown.

From Verrica Pharmaceuticals Inc.'s 10-K filed March 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Verrica Pharmaceuticals Inc. $30.3m 106.2% 52.2%
Scilex Holding Co $31.6m -28.5% -12.0%
Jaguar Health, Inc. $27.8m 135.5% 76.5%
Sunshine Biopharma Inc. $35.3m -2.7% 34.5%
BGM Group Ltd. $37.9m 51.1% —
IM Cannabis Corp. $39.2m -0.7% —

Compare with peers

Head to head: SCLX vs VRCAJAGX vs VRCASBFM vs VRCA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Verrica Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verrica Pharmaceuticals Inc.